-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 19, NMPA's official website released the latest information on approved drugs, and Chengdu Beite Pharmaceutical's digoxin tablets were the first to be reviewed
.
Up to now, 22 products have been reviewed for heart disease treatment drugs
.
.
Up to now, 22 products have been reviewed for heart disease treatment drugs
.
Figure 1: Information on the approved products of Chengdu Better Pharmaceuticals
Source: NMPA official website
Digoxin is a commonly used cardiac glycoside drug, which can slow down the heart rate, effectively improve the symptoms of heart failure and cardiac function, reduce the hospitalization rate and shorten the hospitalization time of patients with severe congestive heart failure.
Atrial fibrillation and other arrhythmias
.
Atrial fibrillation and other arrhythmias
.
Figure 2: The overall sales scale of digoxin (unit: ten thousand yuan)
Source: Mi intranet database
In the first half of 2021, in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as Chinese public medical institutions), the sales growth rate of digoxin reached 56.
74%, of which tablets and injections were the best-selling dosage forms.
, accounting for 56.
46% and 42.
81%, respectively; and in Chinese urban physical pharmacy terminals, digoxin tablets accounted for as high as 90%
.
74%, of which tablets and injections were the best-selling dosage forms.
, accounting for 56.
46% and 42.
81%, respectively; and in Chinese urban physical pharmacy terminals, digoxin tablets accounted for as high as 90%
.
Chengdu Beite Pharmaceutical Co.
, Ltd.
is the first company applying for the consistency evaluation of digoxin tablets , and it has been successfully approved; in addition, 4 companies have reported production of digoxin injection according to the new classification, and the relevant acceptance number is under review and approval
.
, Ltd.
is the first company applying for the consistency evaluation of digoxin tablets , and it has been successfully approved; in addition, 4 companies have reported production of digoxin injection according to the new classification, and the relevant acceptance number is under review and approval
.
According to data from Minet.
com, up to now, 22 products have been reviewed for heart disease
.
com, up to now, 22 products have been reviewed for heart disease
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
Statistics are as of April 20, if there are any omissions, please correct me!
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
Statistics are as of April 20, if there are any omissions, please correct me!
On April 19, NMPA's official website released the latest information on approved drugs, and Chengdu Beite Pharmaceutical's digoxin tablets were the first to be reviewed
.
Up to now, 22 products have been reviewed for heart disease treatment drugs
.
.
Up to now, 22 products have been reviewed for heart disease treatment drugs
.
Figure 1: Information on the approved products of Chengdu Better Pharmaceuticals
Source: NMPA official website
Digoxin is a commonly used cardiac glycoside drug, which can slow down the heart rate, effectively improve the symptoms of heart failure and cardiac function, reduce the hospitalization rate and shorten the hospitalization time of patients with severe congestive heart failure.
Atrial fibrillation and other arrhythmias
.
Atrial fibrillation and other arrhythmias
.
Figure 2: The overall sales scale of digoxin (unit: ten thousand yuan)
Source: Mi intranet database
In the first half of 2021, in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as Chinese public medical institutions), the sales growth rate of digoxin reached 56.
74%, of which tablets and injections were the best-selling dosage forms.
, accounting for 56.
46% and 42.
81%, respectively; and in Chinese urban physical pharmacy terminals, digoxin tablets accounted for as high as 90%
.
74%, of which tablets and injections were the best-selling dosage forms.
, accounting for 56.
46% and 42.
81%, respectively; and in Chinese urban physical pharmacy terminals, digoxin tablets accounted for as high as 90%
.
Chengdu Beite Pharmaceutical Co.
, Ltd.
is the first company applying for the consistency evaluation of digoxin tablets , and it has been successfully approved; in addition, 4 companies have reported production of digoxin injection according to the new classification, and the relevant acceptance number is under review and approval
.
, Ltd.
is the first company applying for the consistency evaluation of digoxin tablets , and it has been successfully approved; in addition, 4 companies have reported production of digoxin injection according to the new classification, and the relevant acceptance number is under review and approval
.
According to data from Minet.
com, up to now, 22 products have been reviewed for heart disease
.
com, up to now, 22 products have been reviewed for heart disease
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
Statistics are as of April 20, if there are any omissions, please correct me!
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
Statistics are as of April 20, if there are any omissions, please correct me!
On April 19, NMPA's official website released the latest information on approved drugs, and Chengdu Beite Pharmaceutical's digoxin tablets were the first to be reviewed
.
Up to now, 22 products have been reviewed for heart disease treatment drugs
.
.
Up to now, 22 products have been reviewed for heart disease treatment drugs
.
Figure 1: Information on the approved products of Chengdu Better Pharmaceuticals
Source: NMPA official website
Digoxin is a commonly used cardiac glycoside drug, which can slow down the heart rate, effectively improve the symptoms of heart failure and cardiac function, reduce the hospitalization rate and shorten the hospitalization time of patients with severe congestive heart failure.
Atrial fibrillation and other arrhythmias
.
Atrial fibrillation and other arrhythmias
.
Figure 2: The overall sales scale of digoxin (unit: ten thousand yuan)
Source: Mi intranet database
In the first half of 2021, in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as Chinese public medical institutions), the sales growth rate of digoxin reached 56.
74%, of which tablets and injections were the best-selling dosage forms.
, accounting for 56.
46% and 42.
81%, respectively; and in Chinese urban physical pharmacy terminals, digoxin tablets accounted for as high as 90%
.
Hospital Hospital Hospital Pharmacy Pharmacy Pharmacy74%, of which tablets and injections were the best-selling dosage forms.
, accounting for 56.
46% and 42.
81%, respectively; and in Chinese urban physical pharmacy terminals, digoxin tablets accounted for as high as 90%
.
Chengdu Beite Pharmaceutical Co.
, Ltd.
is the first company applying for the consistency evaluation of digoxin tablets , and it has been successfully approved; in addition, 4 companies have reported production of digoxin injection according to the new classification, and the relevant acceptance number is under review and approval
.
enterprise enterprise enterprise, Ltd.
is the first company applying for the consistency evaluation of digoxin tablets , and it has been successfully approved; in addition, 4 companies have reported production of digoxin injection according to the new classification, and the relevant acceptance number is under review and approval
.
According to data from Minet.
com, up to now, 22 products have been reviewed for heart disease
.
heart heart heartcom, up to now, 22 products have been reviewed for heart disease
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
Statistics are as of April 20, if there are any omissions, please correct me!
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
Statistics are as of April 20, if there are any omissions, please correct me!
